SG11201901468SA - Antibodies with reduced binding to process impurities - Google Patents
Antibodies with reduced binding to process impuritiesInfo
- Publication number
- SG11201901468SA SG11201901468SA SG11201901468SA SG11201901468SA SG11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA SG 11201901468S A SG11201901468S A SG 11201901468SA
- Authority
- SG
- Singapore
- Prior art keywords
- glaxosmithkline
- road
- international
- antibodies
- hertfordshire
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 April 2018 (12.04.2018) WIP0 1 PCT ill~~~~~~~~ 011101010VIIIOH olo olioluniom Eno iflo oimIE (10) International Publication Number WO 2018/065389 Al (51) International Patent Classification: C07K 16/00 (2006.01) (21) International Application Number: PCT/EP2017/075038 (22) International Filing Date: 03 October 2017 (03.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/404,849 06 October 2016 (06.10.2016) US (71) Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED [GB/GB]; 980 Great West Road, Brentford Middlesex TW8 9GS (GB). (72) Inventors: BOSTEELS, Hella; GlaxoSmithKline, Gun- nels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). CHEN, Shugui; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 (US). FAR- ROW, Kayeleigh; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). KUCIA-TRAN, Richard; GlaxoSmithKline, Gunnels Wood Road, Steve- nage Hertfordshire SG1 2NY (GB). LEWIS, William John Kenneth; GlaxoSmithKline, Gunnels Wood Road, Steve- nage Hertfordshire SG1 2NY (GB). THOMSON, An- drew S.; GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 (US). UDEN, Mark; Glax- oSmithKline, Gunnels Wood Road, Stevenage Hertford- shire SG1 2NY (GB). (74) Agent: BHOGAL, Jasber Kaur; GlaxoSmithKline, Glob- al Patents (CN925.1), 980 Great West Road, Brentford Mid- dlesex TW8 9GS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) 1-1 C/1 00 \"\") (54) Title: ANTIBODIES WITH REDUCED BINDING TO PROCESS IMPURITIES 1 1 (57) : The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also N relates to compositions comprising said variant IgG4 antibodies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404849P | 2016-10-06 | 2016-10-06 | |
| PCT/EP2017/075038 WO2018065389A1 (en) | 2016-10-06 | 2017-10-03 | Antibodies with reduced binding to process impurities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901468SA true SG11201901468SA (en) | 2019-03-28 |
Family
ID=60143674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901468SA SG11201901468SA (en) | 2016-10-06 | 2017-10-03 | Antibodies with reduced binding to process impurities |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11254753B2 (en) |
| EP (1) | EP3523329A1 (en) |
| JP (1) | JP7471819B2 (en) |
| KR (1) | KR20190057083A (en) |
| CN (1) | CN109790216A (en) |
| AU (1) | AU2017338291A1 (en) |
| BR (1) | BR112019004938A2 (en) |
| CA (1) | CA3037264A1 (en) |
| IL (1) | IL265748A (en) |
| MX (1) | MX2019003890A (en) |
| RU (1) | RU2771330C2 (en) |
| SG (1) | SG11201901468SA (en) |
| TW (1) | TW201829453A (en) |
| WO (1) | WO2018065389A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110621697B (en) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | Antagonistic CD40 monoclonal antibodies and uses thereof |
| AR117091A1 (en) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES |
| KR20220010543A (en) * | 2019-05-21 | 2022-01-25 | 리제너론 파아마슈티컬스, 인크. | Methods for Identification and Quantification of Host Cell Proteins |
| TW202140553A (en) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | Antibody molecules to c5ar1 and uses thereof |
| WO2021198880A1 (en) * | 2020-03-31 | 2021-10-07 | Medimmune, Llc | Stabilized igg4 antibodies and uses thereof |
| KR20230142831A (en) | 2021-01-13 | 2023-10-11 | 비스테라, 인크. | Humanized Complement 5A Receptor 1 Antibodies and Methods of Using the Same |
| TW202306985A (en) | 2021-07-12 | 2023-02-16 | 美商建南德克公司 | Structures for reducing antibody-lipase binding |
| US20230303719A1 (en) | 2022-03-03 | 2023-09-28 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2739077A1 (en) * | 2008-10-20 | 2010-04-29 | Robert K. Hickman | Antibodies that bind to il-18 and methods of purifying the same |
| KR101791430B1 (en) | 2009-11-30 | 2017-10-30 | 얀센 바이오테크 인코포레이티드 | ANTIBODY Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| GB201014033D0 (en) * | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| GB201203071D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| RU2016107435A (en) * | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTITATIVE DETERMINATION OF THE PROTEIN OF CELLS-OWNERS IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS |
| SG11201601823TA (en) * | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| AR102198A1 (en) | 2014-10-09 | 2017-02-08 | Regeneron Pharma | PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION |
-
2017
- 2017-10-03 EP EP17787118.3A patent/EP3523329A1/en active Pending
- 2017-10-03 US US16/339,027 patent/US11254753B2/en active Active
- 2017-10-03 SG SG11201901468SA patent/SG11201901468SA/en unknown
- 2017-10-03 TW TW106134267A patent/TW201829453A/en unknown
- 2017-10-03 AU AU2017338291A patent/AU2017338291A1/en not_active Abandoned
- 2017-10-03 CN CN201780061885.8A patent/CN109790216A/en active Pending
- 2017-10-03 WO PCT/EP2017/075038 patent/WO2018065389A1/en unknown
- 2017-10-03 MX MX2019003890A patent/MX2019003890A/en unknown
- 2017-10-03 CA CA3037264A patent/CA3037264A1/en not_active Abandoned
- 2017-10-03 KR KR1020197010590A patent/KR20190057083A/en active IP Right Grant
- 2017-10-03 RU RU2019106819A patent/RU2771330C2/en active
- 2017-10-03 BR BR112019004938A patent/BR112019004938A2/en not_active Application Discontinuation
- 2017-10-03 JP JP2019518304A patent/JP7471819B2/en active Active
-
2019
- 2019-04-01 IL IL265748A patent/IL265748A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018065389A1 (en) | 2018-04-12 |
| RU2771330C2 (en) | 2022-04-29 |
| TW201829453A (en) | 2018-08-16 |
| KR20190057083A (en) | 2019-05-27 |
| CN109790216A (en) | 2019-05-21 |
| JP2019532957A (en) | 2019-11-14 |
| IL265748A (en) | 2019-06-30 |
| JP7471819B2 (en) | 2024-04-22 |
| CA3037264A1 (en) | 2018-04-12 |
| RU2019106819A (en) | 2020-11-06 |
| AU2017338291A1 (en) | 2019-03-14 |
| US20190225708A1 (en) | 2019-07-25 |
| EP3523329A1 (en) | 2019-08-14 |
| US11254753B2 (en) | 2022-02-22 |
| BR112019004938A2 (en) | 2019-06-25 |
| MX2019003890A (en) | 2019-08-12 |
| RU2019106819A3 (en) | 2021-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901468SA (en) | Antibodies with reduced binding to process impurities | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201809331RA (en) | Antibodies recognizing tau | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201811015RA (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| SG11201910066QA (en) | Antibodies recognizing tau | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201900744SA (en) | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201901673SA (en) | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |